SuperworthImmunocore EPS IMCR
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$0.36
- Latest quarter, Q2 FY26
- −$0.02
- Fiscal year 2025
- −$0.69
Immunocore's earnings per share was −$0.36 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.02.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.69 | n/a |
| FY2024 | −$1.02 | n/a |
| FY2023 | −$1.13 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.02 | n/a | −$0.36 | |
| Q1 FY26 | $0.25 | +150% | −$0.54 | |
| Q4 FY25 | −$0.59 | n/a | −$0.69 | |
| Q3 FY25 | $0.00 | −100% | −$0.57 | |
| Q2 FY25 | −$0.20 | n/a | −$0.40 | |
| Q1 FY25 | $0.10 | n/a | −$0.43 | |
| Q4 FY24 | −$0.47 | n/a | −$1.02 | |
| Q3 FY24 | $0.17 | +750% | −$0.95 | |
| Q2 FY24 | −$0.23 | n/a | −$1.10 | |
| Q1 FY24 | −$0.49 | n/a | −$1.22 | |
| Q4 FY23 | −$0.40 | n/a | −$1.13 | |
| Q3 FY23 | $0.02 | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Immunocore's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IMCRImmunocore | −$0.36 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| MGTXMeiraGTx | $0.71 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| Peer median | $0.73 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Immunocore
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.